In oncology, pairing pharmacogenetic data with tumor-specific biomarkers, such as HER2 or BRCA mutations, allows for a dual-target approach that considers both genetic predispositions and tumor characteristics, further personalizing cancer treatments. Here, ERBB2 is linked to cancer.